Nicotinamide - Biorunx
Latest Information Update: 24 Jun 2024
At a glance
- Originator Chungbuk National University
- Developer Biorunx; Chungbuk National University
- Class Amides; Antiacnes; Antibacterials; Nicotinic acids; Small molecules; Vitamins
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Non-small cell lung cancer
- No development reported Cancer
Most Recent Events
- 05 Apr 2024 Nicotinamide is still in phase-II/III trials for Non-small cell lung cancer (Combination therapy, Late-stage disease) in South Korea (PO)
- 05 Apr 2024 Efficacy data from phase-II/III trial in non-small cell lung cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACT-2024)
- 18 Oct 2021 No development reported - Phase-II/III for Non-small cell lung cancer (Combination therapy, Late-stage disease) in South Korea (PO)